TY - JOUR
T1 - Morbidity and mortality among patients with respiratory syncytial virus infection
T2 - a 2-year retrospective review
AU - Anderson, Neil W.
AU - Binnicker, Matthew J.
AU - Harris, Dana M.
AU - Chirila, Razvan M.
AU - Brumble, Lisa
AU - Mandrekar, Jay
AU - Hata, D. Jane
N1 - Publisher Copyright:
© 2016 Elsevier Inc.
PY - 2016/7/1
Y1 - 2016/7/1
N2 - Previous studies have demonstrated high morbidity and mortality for adult patients with respiratory syncytial virus (RSV) infection. We performed a retrospective, multicenter, two-year chart review of all patients (n = 334) testing positive for RSV by the ProFlu + ® Influenza A/B and RSV assay (Hologic, Bedford, MA). We analyzed indicators of morbidity and mortality in children <6 years old, immunocompetent and immunosuppressed adults, and transplant patients. Significant morbidity and mortality was observed among hematopoietic stem cell transplant patients (7.3%, 60-day mortality), solid organ transplant patients (13.3%, 60-day mortality), and COPD patients (12.8%, 60-day mortality). Of the patients positive for RSV, 144 (43.1%) of 334 received antibacterials or antifungals following diagnosis. Of these patients, a bacterial or fungal pathogen was not recovered from 60% of cases. Despite advances in RSV treatment, certain populations appear to be inadequately treated, while others appear to be inappropriately treated with unnecessary antimicrobials.
AB - Previous studies have demonstrated high morbidity and mortality for adult patients with respiratory syncytial virus (RSV) infection. We performed a retrospective, multicenter, two-year chart review of all patients (n = 334) testing positive for RSV by the ProFlu + ® Influenza A/B and RSV assay (Hologic, Bedford, MA). We analyzed indicators of morbidity and mortality in children <6 years old, immunocompetent and immunosuppressed adults, and transplant patients. Significant morbidity and mortality was observed among hematopoietic stem cell transplant patients (7.3%, 60-day mortality), solid organ transplant patients (13.3%, 60-day mortality), and COPD patients (12.8%, 60-day mortality). Of the patients positive for RSV, 144 (43.1%) of 334 received antibacterials or antifungals following diagnosis. Of these patients, a bacterial or fungal pathogen was not recovered from 60% of cases. Despite advances in RSV treatment, certain populations appear to be inadequately treated, while others appear to be inappropriately treated with unnecessary antimicrobials.
KW - Chronic obstructive pulmonary disease
KW - RSV
KW - Transplant
UR - http://www.scopus.com/inward/record.url?scp=84970023412&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84970023412&partnerID=8YFLogxK
U2 - 10.1016/j.diagmicrobio.2016.02.025
DO - 10.1016/j.diagmicrobio.2016.02.025
M3 - Article
C2 - 27179369
AN - SCOPUS:84970023412
SN - 0732-8893
VL - 85
SP - 367
EP - 371
JO - Diagnostic Microbiology and Infectious Disease
JF - Diagnostic Microbiology and Infectious Disease
IS - 3
ER -